The Institut will present at EURETINA the results of the phase III trial OPH1002/3 with Fovista for exudative AMD20/07/2017 · News
Dr. Jordi Monés will attend the Euretina 2017 Congress to explain the overall result of a multicentric phase III trial with Fovista, one in which the Institut de la Mácula has taken part. This involves combination therapy with a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor in exudative AMD. The use of this combined therapy might improve monotherapy with anti-VEGF that already exists for exudative AMD. Due to the capacity of anti-PDGF to induce the detachment of pericytes, in conjunction with the action of anti-VEGF, this might be more effective in halting the formation of new blood vessels and, with it, the progression of the disease. Unfortunately, the study results have concluded that combined therapy with these drugs has no benefit (measured by change in visual acuity) in comparison to monotherapy with anti-VEGF.
Due to the capacity of anti-PDGF to induce the detachment of pericytes, in conjunction with the action of anti-VEGF, this might be more effective in halting the formation of new blood vessels and, with it, the progression of the disease
The results of the trial will be presented at EURETINA’s Update Session 7, Neovascular AMD: Novel insights and lessons learned. To be held on 7-10 September, EURETINA 2017 will take place in Barcelona for the third time in its 17-year history and will feature other interventions by professionals from the Institut de la Màcula. Dr. Marc Biarnés will present a poster related to the European LITE project: “Validation of an adaptive optics scanning laser ophthalmoscope prototype in degenerative disorders: The LITE study” (POS-41696).
The European Society of Retina Specialists is the most important European association of retina specialists. Each edition of its Congress serves to share the latest discoveries in diagnosis and treatment of ocular diseases related to this region of the eye. The Institut de la Màcula, as a leading clinical research centre in AMD, will take active part in the event in order to consolidate the collaborations undertaken with researchers from all over the world and to explore new partnerships.
If you like, you can contact us.Exudative or wet AMD